US › Healthcare

Aprea Therapeutics Inc (APRE)

US · Healthcare · Biotechnology

$0.75+2.67%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Revenue YoY

-100.0%

Net profit

$-3.6M

EPS

$-0.07

EPS estimate

$-0.22

EPS came in at -0.07 against a street estimate of -0.22 — a beat of 68.2%.

Key statistics

Market cap

$9.5M

Forward P/E

0.0

P/B

0.26

Book value

$3.10

EPS (TTM)

$-0.94

52-week high

$1.69

52-week low

$0.55

50-day MA

$0.72

200-day MA

$0.81

Beta

1.63

Analyst view

Analysts rate Aprea Therapeutics Inc a buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $3.73.

Shareholding

Insiders

9.17%

Institutions

18.83%

Largest institutional holders

Fund	Stake
AIGH Capital Management, LLC	8.07%
Vestal Point Capital LP	2.78%
Sphera Funds Management Ltd.	2.14%
Nantahala Capital Management, LLC	1.63%
Geode Capital Management, LLC	0.95%
Scientech Research LLC	0.48%
Diadema Partners LP	0.36%
BNP Paribas Arbitrage, SA	0.32%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Aprea Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.